HPV Associated Disorders Market Size, Share & Trends Analysis Report By Indication (CIN, Cervical Cancer, AIN, Anal Cancer, Genital Warts), By Therapy (Prevention, Treatment), By Distribution Channel, And Segment Forecasts, 2019 - 2026

Published: Aug, 2019 | Pages: 100 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global HPV associated disorders market size is expected to reach USD 23.2 billion by 2026, according to a new report by Grand View Research, Inc. It is estimated to exhibit a CAGR of 4.5% over the forecast period, driven by an increase in disease prevalence and emergence of targeted therapies.

Most cancers associated with HPV have high mortality rates. For instance, cervical cancer has a mortality rate of over 50%. Cervical Intraepithelial Neoplasia (CIN) and Anal Intraepithelial Neoplasia (AIN) could advance into cervical and anal cancer, respectively, in the absence of timely treatment. However, these cancers generally have a slow progression rate, providing possibilities for prevention and treatment.

The prevalence of HPV infection-especially in young women-has increased in the recent decades and continues to increase. Globally, cervical cancer stands as the fourth most prevalent cancer in women. Since HPV is a major causative factor for this, the increasing disease prevalence is a key driving force for market growth.

It is estimated that more than 430 million women in India-15 years or above-are considered at risk for developing HPV associated disorders. The annual incidence of these diseases among Indian women is over 122,900 and disease mortality is around 68,000. In the ancillary market of cervical cancer, India records the highest age-standardized disease incidence in South Asia at 22, followed by Bangladesh at 19.2, Sri Lanka at 13, and Iran at 2.8.

Proactive government initiatives and rise in consumer awareness are likely to drive growth. The CDC initiated National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 1991. The program was created to promote & and facilitate low-cost or free screening for women. Along similar lines, the Indian government recently started an operational framework for mandatory screening for cervical, breast, and oral cancer in people aged 30 years or more. The initiative marked the first nationwide oncological screening program.

Further key findings from the study suggest:

• Vaccines remained the mainstay preventive measure against HPV associated disorders in 2018

• Targeted therapies, such as Avastin and Keytruda, are some of the key revenue generators in the market

• Nearly three fourths of all cases occur in developing and underdeveloped economies

• Asia Pacific is positioned to demonstrate the fastest regional HPV associated disorders market growth

• The CDC recommended the administration of HPV vaccine to adolescents and young adults.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources & third-party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Global HPV Associated Disorders Market Variables, Trends & Scope
3.1. HPV Associated Disorders Market Lineage outlook
3.1.1. Ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Pipeline Analysis
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of HPV related diseases
3.4.1.2. Proactive government initiatives
3.4.1.3. Rise in targeted therapies
3.4.1.4. Increased funding for cancer research
3.4.2. Market restraint analysis
3.4.2.1. Lack of consumer awareness
3.4.2.2. Adverse effeccts
3.5. HPV Associated Disorders Market Analysis Tools
3.5.1. Industry analysis - Porter's
3.5.1.1. Supplier Power: Low due to high demand of HPV vaccines
3.5.1.2. Buyer Power: Moderate due to low number of approved products
3.5.1.3. Substitution Threat: Moderate due to emergence of biosimilars
3.5.1.4. Threat from New Entrant: High due to strong pipeline
3.5.1.5. Competitive Rivalry: High due to increasing mergers & acquisitions by players
3.5.2. PESTEL Analysis
3.5.2.1. Political Landscape
3.5.2.2. Environmental Landscape
3.5.2.3. Social Landscape
3.5.2.4. Technology Landscape
3.5.2.5. Legal Landscape
Chapter 4. HPV Associated Disorders Market: Indication Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Indication Market Share Analysis, 2018 & 2026
4.3. Indication Dashboard
4.4. Global HPV Associated Disorders Market, By Indication, 2014 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
4.5.1. CIN
4.5.1.1. CIN market, 2014 - 2026 (USD Million)
4.5.2. Cervical cancer
4.5.2.1. Cervical cancer market, 2014 - 2026 (USD Million)
4.5.3. AIN
4.5.3.1. AIN market, 2014 - 2026 (USD Million)
4.5.4. Anal Cancer
4.5.4.1. Anal cancer market, 2014 - 2026 (USD Million)
4.5.5. Genital warts
4.5.5.1. Genital warts market, 2014 - 2026 (USD Million)
4.5.6. Others
4.5.6.1. Others market, 2014 - 2026 (USD Million)
Chapter 5. HPV Associated Disorders Market: Therapy Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Therapy Market Share Analysis, 2018 & 2026
5.3. Therapy Dashboard
5.4. Global HPV Associated Disorders Market, By Therapy, 2014 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
5.5.1. Prevention
5.5.1.1. Prevention market, 2014 - 2026 (USD Million)
5.5.2. Treatment
5.5.2.1. Treatment, 2014 - 2026 (USD Million)
Chapter 6. HPV Associated Disorders Market: Distribution Channel Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Distribution Channel Market Share Analysis, 2018 & 2026
6.3. Distribution Channel Dashboard
6.4. Global HPV Associated Disorders Market, By Distribution Channel, 2014 to 2026
6.5. Market Size & Forecasts and Trend Analysis, 2014 to 2026 for the following,
6.5.1. Hospital pharmacies
6.5.1.1. Hospital pharmacies market, 2014 - 2026 (USD Million)
6.5.2. Retail pharmacies
6.5.2.1. Retail pharmacies, 2014 - 2026 (USD Million)
6.5.3. Online pharmacies
6.5.3.1. Online pharmacies, 2014 - 2026 (USD Million)
Chapter 7. HPV Associated Disorders Market: Regional Estimates & Trend analysis
7.1. Regional Market Snapshot
7.2. Regional Market Share and Leading Players, 2018
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
7.4.1. North America
7.4.1.1. North America HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.1.2. U.S.
7.4.1.2.1. U.S. HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.1.3. Canada
7.4.1.3.1. Canada HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.2. Europe
7.4.2.1. Europe HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.2.2. U.K.
7.4.2.2.1. U.K. HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.2.3. Germany
7.4.2.3.1. Germany HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.2.4. Spain
7.4.2.4.1. Spain HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.2.5. France
7.4.2.5.1. France HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.2.6. Italy
7.4.2.6.1. Italy HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.3. Asia Pacific
7.4.3.1. Asia Pacific HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.3.2. China
7.4.3.2.1. China HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.3.3. Japan
7.4.3.3.1. Japan HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.3.4. India
7.4.3.4.1. India HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.3.5. South Korea
7.4.3.5.1. South Korea HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.3.6. Australia
7.4.3.6.1. Australia HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.4. Latin America
7.4.4.1. Latin America HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.4.2. Brazil
7.4.4.2.1. Brazil HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.4.3. Mexico
7.4.4.3.1. Mexico HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.4.4. Argentina
7.4.4.4.1. Argentina HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.5. Middle East Africa
7.4.5.1. MEA HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.5.2. South Africa
7.4.5.2.1. South Africa HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.5.3. Saudi Arabia
7.4.5.3.1. Saudi Arabia HPV Associated Disorders market, 2014 - 2026 (USD Million)
7.4.5.4. UAE
7.4.5.4.1. UAE HPV Associated Disorders market, 2014 - 2026 (USD Million)
Chapter 8. Company Profiles
8.1. Recent developments & impact analysis, by key market participants
8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3. Public Companies
8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
8.3.2. Competitive dashboard analysis
8.3.3. Market differentiators
8.4. Private Companies
8.5. Strategic Framework
8.6. Company Profiles
8.6.1. F. Hoffmann-La Roche AG
8.6.1.1. Company overview
8.6.1.2. Financial performance
8.6.1.3. Product benchmarking
8.6.1.4. Strategic initiatives
8.6.2. Merck & Co., Inc.
8.6.2.1. Company overview
8.6.2.2. Financial performance
8.6.2.3. Product benchmarking
8.6.2.4. Strategic initiatives
8.6.3. GlaxoSmithKline plc
8.6.3.1. Company overview
8.6.3.2. Financial performance
8.6.3.3. Product benchmarking
8.6.3.4. Strategic initiatives
8.6.4. Allergan Plc
8.6.4.1. Company overview
8.6.4.2. Financial performance
8.6.4.3. Product benchmarking
8.6.4.4. Strategic initiatives
8.6.5. Pfizer, Inc
8.6.5.1. Company overview
8.6.5.2. Financial performance
8.6.5.3. Product benchmarking
8.6.5.4. Strategic initiatives
8.6.6. Biocon Ltd.
8.6.6.1. Company overview
8.6.6.2. Financial performance
8.6.6.3. Product benchmarking
8.6.6.4. Strategic initiatives
8.6.7. AstraZeneca plc
8.6.7.1. Company overview
8.6.7.2. Financial performance
8.6.7.3. Product benchmarking
8.6.7.4. Strategic initiatives
8.6.8. Eli Lilly and Company
8.6.8.1. Company overview
8.6.8.2. Financial performance
8.6.8.3. Product benchmarking
8.6.8.4. Strategic initiatives

List of Tables

TABLE 1 List of Abbreviation
TABLE 2 North America HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 3 North America HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 4 North America HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 5 U.S. HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 6 U.S. HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 7 U.S. HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 8 Canada HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 9 Canada HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 10 Canada HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 11 Europe HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 12 Europe HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 13 Europe HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 14 U.K. HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 15 U.K. HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 16 U.K. HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 17 Germany HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 18 Germany HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 19 Germany HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 20 France HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 21 France HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 22 France HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 23 Italy HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 24 Italy HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 25 Italy HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 26 Spain HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 27 Spain HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 28 Spain HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 29 Asia Pacific HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 30 Asia Pacific HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 31 Asia Pacific HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 32 Japan HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 33 Japan HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 34 Japan HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 35 China HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 36 China HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 37 China HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 38 India HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 39 India HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 40 India HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 41 South Korea HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 42 South Korea HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 43 South Korea HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 44 Australia HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 45 Australia HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 46 Australia HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 47 Latin America HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 48 Latin America HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 49 Latin America HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 50 Brazil HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 51 Brazil HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 52 Brazil HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 53 Mexico HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 54 Mexico HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 55 Mexico HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 56 Argentina HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 57 Argentina HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 58 Argentina HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 59 MEA HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 60 MEA HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 61 MEA HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 62 South Africa HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 63 South Africa HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 64 South Africa HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 65 Saudi Arabia HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 66 Saudi Arabia HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 67 Saudi Arabia HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)
TABLE 68 UAE HPV associated disorders market, by indication, 2014 - 2026 (USD Million)
TABLE 69 UAE HPV associated disorders market, by therapy, 2014 - 2026 (USD Million)
TABLE 70 UAE HPV associated disorders market, by distribution channel, 2014 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global HPV associated disorders market - Key market driver analysis
FIG. 7 Global HPV associated disorders market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global HPV associated disorders market - Porter's analysis
FIG. 10 Global HPV associated disorders market - PESTEL analysis
FIG. 11 Global HPV associated disorders market indication outlook key takeaways
FIG. 12 Global HPV associated disorders market: Indication movement analysis
FIG. 13 CIN market estimates, 2014 - 2026 (USD Million)
FIG. 14 Cervical cancer market estimates, 2014 - 2026 (USD Million)
FIG. 15 AIN market estimates, 2014 - 2026 (USD Million)
FIG. 16 Anal cancer market estimates, 2014 - 2026 (USD Million)
FIG. 17 Genital warts market estimates, 2014 - 2026 (USD Million)
FIG. 18 Others market estimates, 2014 - 2026 (USD Million)
FIG. 19 Global HPV associated disorders market therapy outlook key takeaways
FIG. 20 Global HPV associated disorders market: Therapy movement analysis
FIG. 21 Prevention market estimates, 2014 - 2026 (USD Million)
FIG. 22 Treatment market estimates, 2014 - 2026 (USD Million)
FIG. 23 Global HPV associated disorders market distribution channel outlook key takeaways
FIG. 24 Global HPV associated disorders market: Distribution Channel movement analysis
FIG. 25 Hospital pharmacies market estimates, 2014 - 2026 (USD Million)
FIG. 26 Retail pharmacies market estimates, 2014 - 2026 (USD Million)
FIG. 27 Online pharmacies market estimates, 2014 - 2026 (USD Million)
FIG. 28 Regional marketplace: Key takeaways
FIG. 29 Global HPV associated disorders market: Regional movement analysis
FIG. 30 North America HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 31 U.S. HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 32 Canada HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 33 Europe HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 34 U.K. HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 35 Germany HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 36 France HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 37 Spain HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 38 Italy HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 39 Asia Pacific HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 40 Japan HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 41 China HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 42 India HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 43 South Korea HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 44 Australia HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 45 Latin America HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 46 Brazil HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 47 Mexico HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 48 Argentina HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 49 MEA HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 50 South Africa HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 51 Saudi Arabia HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 52 UAE HPV associated disorders market, 2014 - 2026 (USD Million)
FIG. 53 Strategy framework